Novita Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Novita Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#3,663 of 15,742 sponsors by registered trial count).
Novita Pharmaceuticals: 3 sponsored US clinical trials, 1 recruiting.
Novita Pharmaceuticals sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies, with 1 trials.
Upper-quartile sponsor footprint
Novita Pharmaceuticals sits in the upper quartile of the sponsor corpus (#3,663 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
NCT05023486
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
NCT07109414
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
NCT03199586
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
What is open in the Novita Pharmaceuticals pipeline
1 recruiting of 3 indexed (33% open); 1 completed (33%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Novita Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Novita Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Novita Pharmaceuticals page
3 registered trials is a research-attention snapshot, not an endorsement of Novita Pharmaceuticals or any single study.
- 1 of Novita Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies is the condition Novita Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Novita Pharmaceuticals pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.